Clobazam Tablets Recalled for Foreign Tablet Contamination
Amerisource Health Services LLC is recalling Clobazam 10 mg tablets due to the presence of foreign tablets or capsules in some packages. The recall affects 5,178 cartons with Lot #1019594 distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall. The presence of foreign tablets or capsules in prescription medication poses a risk of medication errors or unintended administration of unknown substances to patients, but no illnesses or injuries are reported in the source material.
Plain-English summary
Amerisource Health Services LLC is recalling Clobazam tablets, 10 mg, due to the presence of foreign tablets or capsules found in some packages. The affected product is packaged in cartons containing 30 tablets per carton (3x10 blister cards), distributed nationwide within the United States.
The recall involves 5,178 cartons with Lot #1019594 and an expiration date of 12/31/2025. Consumers who have received packages from this lot should stop using the product and contact their pharmacy or healthcare provider immediately for guidance.
The recalled product
- Product
- CLOBAZAM (CLOBAZAM)
- Brand
- CLOBAZAM
- Manufacturer
- Amerisource Health Services LLC
- Hazard
- foreign-tablet-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 1019594
- Exp. Date 12/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CLOBAZAM
- HighClobazam tablets recalled for contamination with foreign tablets
FDA (Drugs) · 2025-01-22
- HighClobazam tablets recalled nationwide for residual solvent deviation
FDA (Drugs) · 2024-02-28
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27